bisphosphonate-related osteonecrosis of the jaw
Conditions
Interventions
teriparatide(daily)
teriparatide(weekly)
Sponsors
Kyushu Dental University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who are eligible for teriparatide treatment for osteoporosis Patients who have been diagnosed with BRONJ Patients refractory to conservative treatment with BRONJ Outpatients Patients with documented consent to participate in this study
Exclusion criteria
Exclusion criteria: Patients with hypercalcemia Patients who are considered to be at high risk of developing osteosarcoma as follows (a) Patients with Paget's disease of bone (b) Patients with unexplained high alkaline phosphatase levels (c) Young patients whose epiphyseal line has not yet closed (d) Patients who have received radiation therapy that may affect bone in the past. Patients with primary malignant bone tumors or metastatic bone tumors Patients with metabolic bone diseases other than osteoporosis (hyperparathyroidism, etc.) Pregnant women, women who may become pregnant, and lactating women Patients with a history of hypersensitivity to teriparatide components or teriparatide acetate Patients with serious complications such as cancer, cardiac disease, liver disease, and renal disorder Patients currently using an activated vitamin D preparation or a digitalis preparation Patients who are unable to give informed consent Patients who are judged by the physician to be unsuitable for teriparatide treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement of necrotic bone exposure bone formation | — |
Countries
Japan
Contacts
Public ContactDaigo Yoshiga
Kyshu Dental University Oral Medicine
Outcome results
None listed